查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1623479

全球植入式药物传输设备市场规模：依产品、应用、技术、最终用户、地区划分的范围及预测

Global Implantable Drug Delivery Devices Market Size By Product, By Application, By Technology, By End-User And By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

植入式药物输送装置的市场规模及预测

植入式药物输送设备市场规模预计在 2023 年达到 255.2 亿美元，预计在 2024 年至 2031 年期间的复合年增长率为 7.25%，到 2031 年将达到 403.5 亿美元。 据预测。允许特定部位给药的可植入药物输送装置是一种能够有效输送低浓度药物的替代系统。此功能可提高患者的依从性，同时最大限度地减少潜在的副作用。这些装置有助于治疗剂的持续释放，无需反覆针刺即可注射药物或液体。植入式药物输送装置避免了因静脉注射而住院的现象。

这些装置由被聚合物或药物-聚合物混合物包围的药物储存器组成，被插入体内的所需部位，聚合物在此降解，并以预定的速率释放药物。

植入式药物传输装置的全球市场动态

影响植入式药物传输设备市场的关键市场动态

主要市场驱动因子

慢性病发生率不断上升：

由于人口老化、不健康的生活方式和诊断方法的改进等因素，癌症、心血管疾病和糖尿病等慢性疾病在世界各地变得越来越普遍。日益加重的负担推动了对有效治疗方案的需求，而植入式药物传输系统已成为控制和标靶药物释放的宝贵工具。

技术进步：

材料科学、微加工和生物工程的不断进步正在推动更复杂和有效的植入式药物输送装置的发展。这些进步可以实现控製药物释放、改善生物相容性和标靶输送等功能，最终改善患者的治疗效果并推动市场成长。

越来越重视微创手术：

由于恢復时间更快、患者不适感更少，人们更倾向于选择微创手术而非传统手术，这是推动植入式药物传输市场发展的主要因素。这些设备提供了一种微创的替代传统药物输送方法，例如口服药物和注射，使其成为患者和医疗保健提供者都具有吸引力的选择。

主要问题

严格的监理要求：

由于体内植入异物有固有风险，因此植入式药物输送系统的核准程序受到严格监管。这需要严格的测试和临床试验以确保安全性、有效性和生物相容性，从而导致漫长而昂贵的开发时间。这可能会严重阻碍创新并延迟向患者提供救命的治疗。

开发及製造成本高：

由于涉及的技术复杂，并且需要高品质的材料和先进的製造工艺，植入式药物传输系统的开发和製造成本通常很高。这将要求大公司承担大量的前期成本，这可能会影响获利能力并限制获得这些技术的机会，特别是对于中低收入国家的患者而言。

报销课题与市场准入：

即使获得监管部门批准，从保险公司和医疗保健提供者获得这些先进疗法的足够报销仍然很困难。这些限制可能会阻碍患者获得可能改变生活的治疗方法，并抑制植入式药物传输系统市场的成长。此外，进入医疗保健体系和法规不同的地区市场对在该市场运营的公司也构成了另一个障碍。

主要趋势

加强一体化与策略联盟：

随着大型製药和医疗器材公司寻求透过合併、收购和策略联盟来加强其地位，植入式药物输送市场也正在经历整合。这些合作旨在利用互补的技术和专业知识来加速产品开发和上市。

探索扩充应用：

植入式药物传递系统已被探索应用于传统药物传递以外的广泛的医疗治疗领域，包括荷尔蒙替代疗法、疼痛管理、避孕和癌症治疗。应用的多样化正在推动市场创新和投资。

关注病人的便利性与依从性：

植入式药物传递系统有可能消除频繁给药和服药的需要，从而提高患者的依从性和便利性。这对于需要长期药物治疗的慢性病患者尤其有益。

目录

第 1 章 植入式药物输送装置的全球市场：简介

    市场概况
  • 研究范围
  • 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

  • 资料探勘
  • 验证
  • 主要来源
  • 资料来源列表

第 4 章 植入式药物输送装置的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 阻碍因素
    • 机会
  • 波特五力模型
  • 价值链分析
  • 监理框架

5. 全球植入式药物传输设备市场（依技术划分）

  • 概述
  • 主动药物输送装置
  • 被动药物输送装置
    • 可生物降解
    • 不可生物降解
第六章全球植入式药物传输设备市场（依产品）
  • 概述
  • 生物可吸收支架
  • 避孕药物输送装置
  • 眼内药物输送装置
  • 冠状动脉药物洗脱支架
  • 近距离放射治疗种子
  • 药物输液泵
第七章全球植入式药物传输设备市场（依应用）
  • 概述
  • 心血管疾病
  • 肿瘤学
  • 糖尿病
  • 眼科
  • 自体免疫疾病
  • 避孕
  • 其他

8. 全球植入式药物传输设备市场（依最终用户划分）

  • 概述
  • 医院和诊所
  • 门诊手术中心
  • 专业中心
  • 其他

第 9 章。
  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
    亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 世界其他地区
    • 中东和非洲

第 10 章。
  • 概述
  • 各公司的市占率
  • 供应商概况
  • 主要发展策略

第 11 章 公司简介

  • Bayer
  • Boston Scientific
  • Medtronic
  • Merck & Co. Inc.
  • Allergan Inc.
  • Bausch And Lomb Inc.
  • Ithetis
  • Nucletron
  • Genetech Inc.
  • Theragenics

第 12 章 重大进展

  • 产品发布/开发
  • 合併和收购
  • 业务扩展
  • 伙伴关係和合作关係

第 13 章附录

  • 相关研究
简介目录
Product Code: 23845

Implantable Drug Delivery Devices Market Size And Forecast

Implantable Drug Delivery Devices Market size is estimated at USD 25.52 Billion in 2023 and is projected to reach USD 40.35 Billion by 2031, growing at a CAGR of 7.25% from 2024 to 2031. Implantable drug delivery devices, which enable site-specific drug administration, are an alternative system capable of achieving effective delivery with lower drug concentrations. This capability allows for the minimization of potential side effects while increasing patient compliance. The sustained release of a therapeutic agent is facilitated by these devices, which administer drugs and fluids without the need for the repeated insertion of needles. Hospitalization for intravenous infusion is avoided by implantable drug delivery devices.

Consisting of a drug reservoir surrounded by a polymer or a drug-polymer mixture, these devices release the drug at a pre-determined rate as the polymer degrades upon insertion into a desired area in the body.

Global Implantable Drug Delivery Devices Market Dynamics

The key market dynamics that are shaping the Implantable Drug Delivery Devices Market include:

Key Market Drivers

Rising Prevalence of Chronic Diseases:

Chronic diseases like cancer, cardiovascular diseases, and diabetes are increasingly prevalent worldwide, driven by factors such as an aging population, unhealthy lifestyles, and improved diagnostics. The demand for effective treatment options is fueled by this rising burden, making implantable drug delivery systems a valuable tool for controlled and targeted drug release, potentially improving treatment efficacy and patient compliance.

Technological Advancements:

Continuous advancements in materials science, microfabrication, and bioengineering are leading to the development of more sophisticated and effective implantable drug-delivery devices. Features like controlled drug release, improved biocompatibility, and targeted delivery are enabled by these advancements, ultimately leading to better patient outcomes and driving market growth.

Growing Focus on Minimally Invasive Procedures:

The increasing preference for minimally invasive procedures over traditional surgeries due to faster recovery times and less patient discomfort is a significant driver for the Implantable Drug Delivery Devices Market. These devices offer a minimally invasive alternative to traditional drug delivery methods like oral medications or injections, making them an attractive option for both patients and healthcare providers.

Key Challenges

Stringent Regulatory Requirements:

Due to the inherent risks associated with implanting foreign objects in the body, the approval process for implantable drug delivery systems is highly regulated. This involves subjecting them to rigorous testing and clinical trials to ensure safety, efficacy, and biocompatibility, resulting in lengthy and expensive development timelines. Innovation can be significantly impeded, and the availability of life-saving treatments to patients may be delayed as a consequence.

High Cost of Development and Production:

Implantable drug delivery systems often incur high costs in development and manufacturing due to the involvement of complex technologies and the necessity for high-quality materials and advanced manufacturing processes. This leads to substantial upfront costs for companies, impacting their profitability and potentially restricting access to these technologies for patients, particularly in low- and middle-income countries.

Reimbursement Challenges and Market Access:

Even following regulatory approval, securing adequate reimbursement from insurance companies and healthcare providers for these advanced therapies can be challenging. This limitation can impede patient access to these potentially life-changing treatments, thereby hindering market growth for implantable drug delivery systems. Additionally, gaining market access in different regions with varying healthcare systems and regulations presents another obstacle for companies operating in this market.

Key Trends

Consolidation Being Witnessed and Strategic Partnerships:

Consolidation was being witnessed in the Implantable Drug Delivery Devices Market as larger pharmaceutical and medical device companies were being sought to strengthen their positions through mergers, acquisitions, and strategic partnerships. These collaborations aimed to leverage complementary technologies and expertise to accelerate product development and market penetration.

Exploration of Expanding Applications:

Implantable drug delivery systems were being explored for a wide range of therapeutic applications beyond traditional drug delivery, including hormone replacement therapy, pain management, contraception, and cancer treatment. This diversification of applications was driving innovation and investment in the market.

Focus on Patient Convenience and Compliance:

The potential to improve patient compliance and convenience was offered by implantable drug delivery systems by eliminating the need for frequent dosing or administration. This was particularly beneficial for patients with chronic conditions who required long-term medication therapy.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Implantable Drug Delivery Devices Market Regional Analysis

Here is a more detailed regional analysis of the Implantable Drug Delivery Devices Market:

North America

A well-established healthcare infrastructure, including advanced medical facilities and research institutions, fosters innovation and the adoption of implantable drug delivery technologies.

Stringent regulatory standards, particularly by the FDA, ensure rigorous evaluation and approval processes for implantable drug delivery devices, enhancing confidence in their safety and efficacy.

Substantial investments in research and development are attracted by the region is facilitating the development of cutting-edge implantable drug delivery technologies and thereby, driving market growth.

The demand for effective and long-term drug delivery solutions is driven by the rising burden of chronic diseases such as cancer, cardiovascular diseases, and diabetes in North America, further solidifying the region's dominance in the market.

Asia Pacific

Market growth is driven by increasing healthcare expenditure in countries like China and India.

Demand for long-term drug delivery solutions is boosted by the rising prevalence of chronic diseases in the region.

Market expansion is contributed to by technological advancements and the growing adoption of innovative medical devices.

The market in Asia Pacific is further propelled by government initiatives to improve healthcare infrastructure and access to advanced treatments.

Global Implantable Drug Delivery Devices Market: Segmentation Analysis

The Global Implantable Drug Delivery Devices Market is Segmented on the basis of Product, Application, Technology, End-User, and Geography.

Implantable Drug Delivery Devices Market, By Product

  • Bio-absorbable stents
  • Contraceptive Drug Delivery Devices
  • Intraocular Drug Delivery Devices
  • Coronary Drug Eluting Stents
  • Brachytherapy Seeds
  • Drug Infusion Pumps

Based on Product, the market is segmented into Bio-absorbable stents, Contraceptive Drug Delivery Devices, Intraocular Drug Delivery Devices, Coronary Drug Eluting Stents, Brachytherapy Seeds, and Drug Infusion Pumps. The highest market share in the Implantable Drug Delivery Devices Market is held by the coronary drug-eluting stents segment. This dominance is primarily attributed to the widespread prevalence of cardiovascular diseases worldwide, resulting in a substantial demand for effective treatment options such as drug-eluting stents. Advancements in stent technologies and procedural techniques further contribute to the segment's market dominance.

Implantable Drug Delivery Devices Market, By Application

  • Cardiovascular Diseases
  • Oncology
  • Diabetes
  • Ophthalmology
  • Autoimmune Diseases
  • Birth Control & Contraception
  • Others

Based on Application, the market is segmented into Cardiovascular Diseases, Oncology, Diabetes, Ophthalmology, Autoimmune Diseases, Birth Control & Contraception, and Others. The highest market share in the Implantable Drug Delivery Devices Market is held by the cardiovascular diseases segment. This dominance is primarily attributed to the significant prevalence of cardiovascular conditions globally, which necessitates effective and targeted drug delivery solutions. The segment's market leadership is further contributed to by continuous advancements in cardiovascular therapies and procedures.

Implantable Drug Delivery Devices Market, By Technology

  • Active Drug Delivery Device
  • Passive Drug Delivery Device
  • Biodegradable
  • Non-biodegradable

Based on Technology, the market is segmented into Active Drug Delivery Devices and Passive Drug Delivery Devices. From which, Passive drug eluting device technology is projected to hold a major revenue share in the Implantable Drug Delivery Devices Market. This dominance of the segment is attributable to the large-scale applications of passive drug-eluting solutions in the fields of oncology, cardiology, pain management, contraception, etc.

Implantable Drug Delivery Devices Market, By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Specialty Centers
  • Others

Based on End-User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Specialty Centers, and Others. The Implantable Drug Delivery Devices Market's highest market share is held by hospitals & clinics. This dominance is primarily attributed to the widespread utilization of these facilities for the diagnosis, treatment, and management of various medical conditions necessitating implantable drug delivery systems. Specialized departments and resources dedicated to implantable drug delivery within hospitals and clinics further contribute to their market leadership.

Key Players

  • The "Implantable Drug Delivery Devices Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
  • Bayer, Boston Scientific, Medtronic, Merck & Co., Inc., Allergan, Inc., Bausch AndLomb, Inc., Ithetis, Nucletron, Genetech, Inc., Theragenics, Psivida, Kinamed, Inc., K2M, Inc., Mako Surgical Corp., and Varian Medical System.

Our market analysis includes a section specifically devoted to such major players, where our analysts give an overview of each player's financial statements, along with product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned players globally are also included in the competitive landscape section.

  • Implantable Drug Delivery Devices Market Recent Developments
  • In August 2022, the Onyx Frontier drug-eluting stent (DES) was launched by Medtronic, after receiving CE Mark approval. This stent features an innovative delivery system and is built upon the success of their previous DES products.
  • In February 2023, FDA approval was received by Boston Scientific for their Eluvia drug-eluting stent intended for the treatment of coronary artery disease. This stent employs a novel polymer designed to control drug release and potentially enhance patient outcomes.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis
  • 4.5 Regulatory Framework

5 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY TECHNOLOGY

  • 5.1 Overview
  • 5.2 Active Drug Delivery Device
  • 5.3 Passive Drug Delivery Device
    • 5.3.1 Biodegradable
    • 5.3.2 Non-biodegradable

6 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT

  • 6.1 Overview
  • 6.2 Bio-absorbable stents
  • 6.3 Contraceptive Drug Delivery Devices
  • 6.4 Intraocular Drug Delivery Devices
  • 6.5 Coronary Drug Eluting Stents
  • 6.6 Brachytherapy Seeds
  • 6.7 Drug Infusion Pumps

7 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Cardiovascular Diseases
  • 7.3 Oncology
  • 7.4 Diabetes
  • 7.5 Ophthalmology
  • 7.6 Autoimmune Diseases
  • 7.7 Birth Control & Contraception
  • 7.8 Others

8 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY END-USER

  • 8.1 Overview
  • 8.2 Hospitals & Clinics
  • 8.3 Ambulatory Surgical Centers
  • 8.4 Specialty Centers
  • 8.5 Others

9 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
  • 9.6 Rest of the World
    • 9.6.1 Middle East And Africa

10 GLOBAL IMPLANTABLE DRUG DELIVERY DEVICES MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Share
  • 10.3 Vendor Landscape
  • 10.4 Key Development Strategies

11 COMPANY PROFILES

  • 11.1 Bayer
    • 11.1.1 Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Outlook
    • 11.1.4 Key Developments
  • 11.2 Boston Scientific
    • 11.2.1 Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Outlook
    • 11.2.4 Key Developments
  • 11.3 Medtronic
    • 11.3.1 Overview
    • 11.3.2 Financial Performance
    • 11.3.3 Product Outlook
    • 11.3.4 Key Developments
  • 11.4 Merck & Co. Inc.
    • 11.4.1 Overview
    • 11.4.2 Financial Performance
    • 11.4.3 Product Outlook
    • 11.4.4 Key Developments
  • 11.5 Allergan Inc.
    • 11.5.1 Overview
    • 11.5.2 Financial Performance
    • 11.5.3 Product Outlook
    • 11.5.4 Key Developments
  • 11.6 Bausch And Lomb Inc.
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Developments
  • 11.7 Ithetis
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Nucletron
    • 11.8.1 Overview
    • 11.8.2 Financial Performance
    • 11.8.3 Product Outlook
    • 11.8.4 Key Developments
  • 11.9 Genetech Inc.
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Developments
  • 11.10 Theragenics
    • 11.10.1 Overview
    • 11.10.2 Financial Performance
    • 11.10.3 Product Outlook
    • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

  • 12.1 Product Launches/Developments
  • 12.2 Mergers and Acquisitions
  • 12.3 Business Expansions
  • 12.4 Partnerships and Collaborations

13 Appendix

  • 13.1 Related Research